The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Kedrab Market Become By 2030 Compared To 2026?
The growth witnessed in the historic period can be attributed to severe rabies fatality rates, the widespread reliance on immunoglobulin products, constrained early access to vaccines, established public health emergency protocols, and the management of rabies cases predominantly in hospital settings.
During the forecast period, growth can be ascribed to a rise in animal bite incidents, the expansion of rabies awareness initiatives, an increase in emergency care infrastructure, enhanced access to monoclonal antibodies, and greater government investment in rabies prevention.
Key trends in the forecast period involve the growing application of rabies passive immunization, the broadening of post-exposure prophylaxis programs, a heightened focus on controlling zoonotic diseases, an increased demand for emergency immunotherapy, and the strengthening of public health response systems.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20124&type=smp
What Influential Factors Are Boosting The Kedrab Market Demand?
The growing number of rabies cases is anticipated to stimulate the kedrab market in the future. Rabies, an almost always fatal illness contracted from exposure to rabid animals, presents a serious public health challenge, particularly in areas lacking sufficient access to vaccines. The heightened occurrence of rabies is primarily fueled by inadequate vaccination rates among domestic animals, constrained access to post-exposure prophylaxis, and the widespread presence of rabies in wildlife, especially within underserved regions. Kedrab functions as a human rabies immunoglobulin, delivering immediate passive immunity to individuals exposed to the rabies virus, thus offering crucial protection until vaccination can generate active immunity. For instance, in April 2024, the South Dakota Department of Health, a US-based government agency, indicated that approximately 20 animals in South Dakota were confirmed to have rabies in 2023, representing a 122% increase from the 9 cases reported in 2022. This demonstrates how the increasing incidence of rabies propels the kedrab market.
What Are The Major Segment Categories Within The Kedrab Market?
The kedrab market covered in this report is segmented –
1) By Indication: Post-Exposure Prophylaxis For Rabies, Treatment For Patients Exposed To Suspected Rabid Animals
2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution
3) By Route Of Administration: Intramuscular Injection, Subcutaneous Injection
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Emergency Departments, Specialty Clinics, Public Health Organizations
What Trends Are Influencing The Future Of The Kedrab Market?
Major companies operating in the kedrab market are primarily focused on developing innovative solutions and securing regulatory mechanisms, such as exclusive licensing and distribution continuation notices, to bolster KEDRAB’s commercial reach and market presence in the U.S. An exclusive licensing and distribution continuation notice represents a formal statement from a pharmaceutical or biotechnology company, signifying the extension or renewal of an existing agreement that confers exclusive rights to license, distribute, or commercialize a specific product. For example, in July 2023, Kamada Ltd., an Israel-based plasma-derived biopharmaceutical company, announced that Kedrion Biopharma exercised its option to extend the exclusive U.S. distribution agreement for KEDRAB, a human rabies immune globulin utilized for post-exposure prophylaxis. KEDRAB delivers immediate passive immunity against rabies following potential exposure, with demonstrated efficacy, safety, and regulatory approval in the U.S. The two-year extension guarantees sustained availability and supply stability, thereby reinforcing Kedrion’s commercial distribution infrastructure and strategic presence in the U.S. immunoglobulin market, ultimately enhancing patient access and public health preparedness.
Who Are The Firms Contributing To The Kedrab Market Ecosystem?
Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.
Access The Complete Kedrab Market Report:
https://www.thebusinessresearchcompany.com/report/kedrab-global-market-report
Which Area Represents The Largest Portion Of The Kedrab Market?
North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedrab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model